Myomo Reveals its $100 Revenue Goal During Investor Day

Myomo, Inc. (NYSE:MYO) is one of the 10 Best Small Cap Robotics Stocks to Buy Now. On June 18, the company held an Investor and Analyst Day to assess the company’s business model and long-term aspirations.

The company cited its Q1 FY2025 performance and mentioned that its lead generation capabilities helped recover the challenges faced earlier in the quarter. Myomo’s management highlighted that prospective MyoPro patients are an untapped market, and the company is yet to reach saturation with its advertising.

The company also presented its goal of $100 million in annual revenue by 2028. Of this, $15 million of revenue is to come from international customers and $20 million from its O&P channel.

Myomo, Inc. (NYSE:MYO) is a wearable robotics company that offers functionality to patients suffering from neurological disorders and upper limb paralysis.

While we acknowledge the potential of MYO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.